Zacks Investment Research upgraded shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) from a sell rating to a hold rating in a research note published on Wednesday.

According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “

Several other equities research analysts have also recently weighed in on the stock. Cowen and Company reiterated a buy rating and issued a $19.00 target price on shares of Oxford Immunotec Global PLC in a research note on Thursday, September 28th. BTIG Research assumed coverage on shares of Oxford Immunotec Global PLC in a research note on Thursday, September 28th. They issued a buy rating and a $21.00 target price for the company. Finally, Piper Jaffray Companies reiterated a buy rating and issued a $26.00 target price on shares of Oxford Immunotec Global PLC in a research note on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of $22.00.

Shares of Oxford Immunotec Global PLC (NASDAQ OXFD) opened at 16.77 on Wednesday. Oxford Immunotec Global PLC has a 52 week low of $11.88 and a 52 week high of $19.51. The firm’s market cap is $386.98 million. The firm’s 50-day moving average price is $15.83 and its 200 day moving average price is $15.64.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its quarterly earnings results on Tuesday, August 1st. The company reported ($0.32) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.32). Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The company had revenue of $26.10 million for the quarter, compared to the consensus estimate of $25.05 million. During the same period last year, the business posted ($0.29) earnings per share. The firm’s revenue was up 35.9% compared to the same quarter last year. Equities analysts anticipate that Oxford Immunotec Global PLC will post ($1.61) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Oxford Immunotec Global PLC (OXFD) Stock Rating Upgraded by Zacks Investment Research” was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.watchlistnews.com/oxford-immunotec-global-plc-oxfd-stock-rating-upgraded-by-zacks-investment-research/1616529.html.

In other Oxford Immunotec Global PLC news, CEO Peter Wrighton-Smith sold 55,000 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $16.78, for a total transaction of $922,900.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $15.82, for a total transaction of $47,460.00. Following the transaction, the director now owns 18,000 shares of the company’s stock, valued at approximately $284,760. The disclosure for this sale can be found here. In the last quarter, insiders sold 90,110 shares of company stock valued at $1,523,514. 8.11% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in OXFD. Teachers Advisors LLC lifted its stake in Oxford Immunotec Global PLC by 19.6% during the fourth quarter. Teachers Advisors LLC now owns 39,932 shares of the company’s stock worth $597,000 after purchasing an additional 6,550 shares during the period. Nationwide Fund Advisors lifted its stake in Oxford Immunotec Global PLC by 1.9% during the first quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock worth $213,000 after purchasing an additional 254 shares during the period. Russell Investments Group Ltd. bought a new position in Oxford Immunotec Global PLC during the first quarter worth about $1,135,000. Wells Fargo & Company MN lifted its stake in Oxford Immunotec Global PLC by 129.2% during the first quarter. Wells Fargo & Company MN now owns 65,937 shares of the company’s stock worth $1,021,000 after purchasing an additional 37,163 shares during the period. Finally, American International Group Inc. lifted its stake in Oxford Immunotec Global PLC by 7.1% during the first quarter. American International Group Inc. now owns 13,668 shares of the company’s stock worth $212,000 after purchasing an additional 904 shares during the period. Hedge funds and other institutional investors own 79.21% of the company’s stock.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global PLC (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.